Advertisement

Clinical and Translational Oncology

, Volume 20, Issue 9, pp 1175–1184 | Cite as

The glycosyltransferase ST6Gal-I is enriched in cancer stem-like cells in colorectal carcinoma and contributes to their chemo-resistance

  • H. Cui
  • S. Yang
  • Y. Jiang
  • C. Li
  • Y. Zhao
  • Y. Shi
  • Y. Hao
  • F. Qian
  • B. TangEmail author
  • P. YuEmail author
Research Article

Abstract

Purpose

Presence of cancer stem cells (CSCs) contributes to tumor outgrowth, chemo-resistance and relapse in some cancers including colorectal carcinoma (CRC). The current characterization methods of CSCs in CRC only allows enrichment of CSCs but not their purification. Recent reports showed that ST6 beta-galactoside alpha-2,6-sialyltransferase 1 (ST6Gal-I) plays an essential role in protecting tumor cells against harsh environment like oxidative stress and nutrient deprivation. Therefore, whether ST6Gal-I may be highly expressed in CSCs or whether it may enhance resistance of tumor cells to chemotherapy deserves exploration.

Method

ST6Gal-I levels were determined in CRC specimens, compared to paired normal colorectal tissue, and examined in CD133+ vs CD133− CRC cells, and CD44+ vs CD44− CRC cells. ST6Gal-I levels and their association with patient survival were examined. In vivo, 2 CRC cell lines Caco-2 and SW48 were transduced with two lentiviruses, one lentivirus carrying a green fluorescent protein reporter and a luciferase reporter under a cytomegalovirus promoter to allow tracing tumor cells by both fluorescence and luciferase activity, and one lentivirus carrying a nuclear red fluorescent protein under the control of ST6Gal-I promoter to allow separation of ST6Gal-I+ vs ST6Gal-I− CRC cells. Tumor sphere formation, resistance to fluorouracil-induced apoptosis, and frequency of tumor formation after serial adoptive transplantation were done on ST6Gal-I+ vs ST6Gal-I− CRC cells.

Result

ST6Gal-I levels were significantly upregulated in clinically obtained CRC specimens, compared to paired normal colorectal tissue. Poorer patient survival was detected in ST6Gal-I-high CRC, compared to ST6Gal-I-low subjects. Higher levels of ST6Gal-I were detected in CD133+ CRC cells than CD133− CRC cells, and in CD44+ CRC cells than in CD44− CRC cells. Compared to ST6Gal-I− CRC cells, ST6Gal-I+ CRC cells generated significantly more tumor spheres in culture, were more resistant to fluorouracil-induced apoptosis likely through upregulating cell autophagy, and generated tumor more frequently after serial adoptive transplantation.

Conclusion

ST6Gal-I may be highly expressed in the cancer stem-like cells in CRC and enhances cancer cell resistance to chemotherapy.

Keywords

Cancer stem cells (CSCs) Colorectal carcinoma (CRC) ST6 beta-galactoside alpha-2,6-sialyltransferase 1 (ST6Gal-I) 

Notes

Compliance with ethical standards

Conflict of interest

The authors declared no competing interests.

Ethical approval

All the experimental protocols including animal procedures have been approved by the research committee at the Third Military Medical University and carried out in accordance with the guideline. Resected CRC specimens were obtained together with the paired adjacent non-tumor colorectal tissue (NT) from 66 patients since 2006 through 2011 at Third Military Medical University, with signed approval obtained from the involved patients.

References

  1. 1.
    Garza-Trevino EN, Said-Fernandez SL, Martinez-Rodriguez HG. Understanding the colon cancer stem cells and perspectives on treatment. Cancer Cell Int. 2015;15(1):2.  https://doi.org/10.1186/s12935-015-0163-7.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    De Maio G, Zama E, Rengucci C, Calistri D. What influences preneoplastic colorectal lesion recurrence? Oncotarget. 2017;8(7):12406–16.  https://doi.org/10.18632/oncotarget.13628.PubMedCrossRefGoogle Scholar
  3. 3.
    Curtin JC, Lorenzi MV. Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget. 2010;1(7):552–66.  https://doi.org/10.18632/oncotarget.101016.CrossRefGoogle Scholar
  4. 4.
    Kemper K, Grandela C, Medema JP. Molecular identification and targeting of colorectal cancer stem cells. Oncotarget. 2010;1(6):387–95.  https://doi.org/10.18632/oncotarget.101003.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Zeuner A, Todaro M, Stassi G, De Maria R. Colorectal cancer stem cells: from the crypt to the clinic. Cell Stem Cell. 2014;15(6):692–705.  https://doi.org/10.1016/j.stem.2014.11.012.CrossRefPubMedGoogle Scholar
  6. 6.
    Wang T, Shigdar S, Gantier MP, Hou Y, Wang L, Li Y, et al. Cancer stem cell targeted therapy: progress amid controversies. Oncotarget. 2015;6(42):44191–206.  https://doi.org/10.18632/oncotarget.6176.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445(7123):111–5.  https://doi.org/10.1038/nature05384.CrossRefPubMedGoogle Scholar
  8. 8.
    O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445(7123):106–10.  https://doi.org/10.1038/nature05372.CrossRefPubMedGoogle Scholar
  9. 9.
    Du L, Wang H, He L, Zhang J, Ni B, Wang X, et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res. 2008;14(21):6751–60.  https://doi.org/10.1158/1078-0432.CCR-08-1034.CrossRefPubMedGoogle Scholar
  10. 10.
    Zeilstra J, Joosten SP, Dokter M, Verwiel E, Spaargaren M, Pals ST. Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis. Cancer Res. 2008;68(10):3655–61.  https://doi.org/10.1158/0008-5472.CAN-07-2940.CrossRefPubMedGoogle Scholar
  11. 11.
    Wielenga VJ, Smits R, Korinek V, Smit L, Kielman M, Fodde R, et al. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol. 1999;154(2):515–23.  https://doi.org/10.1016/S0002-9440(10)65297-2.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Wu Y, Wu PY. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev. 2009;18(8):1127–34.  https://doi.org/10.1089/scd.2008.0338.CrossRefPubMedGoogle Scholar
  13. 13.
    Yan Y, Zuo X, Wei D. Concise review: emerging role of CD44 in cancer stem cells: a promising biomarker and therapeutic target. Stem Cells Transl Med. 2015;4(9):1033–43.  https://doi.org/10.5966/sctm.2015-0048.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Taniguchi H, Moriya C, Igarashi H, Saitoh A, Yamamoto H, Adachi Y, et al. Cancer stem cells in human gastrointestinal cancer. Cancer Sci. 2016;107(11):1556–62.  https://doi.org/10.1111/cas.13069.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Chen C, Ma J, Lazic A, Backovic M, Colley KJ. Formation of insoluble oligomers correlates with ST6Gal I stable localization in the golgi. J Biol Chem. 2000;275(18):13819–26.CrossRefPubMedGoogle Scholar
  16. 16.
    Britain CM, Dorsett KA, Bellis SL. The glycosyltransferase ST6Gal-I protects tumor cells against serum growth factor withdrawal by enhancing survival signaling and proliferative potential. J Biol Chem. 2017;292(11):4663–73.  https://doi.org/10.1074/jbc.M116.763862.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Schultz MJ, Holdbrooks AT, Chakraborty A, Grizzle WE, Landen CN, Buchsbaum DJ, et al. The tumor-associated glycosyltransferase ST6Gal-I regulates stem cell transcription factors and confers a cancer stem cell phenotype. Cancer Res. 2016;76(13):3978–88.  https://doi.org/10.1158/0008-5472.CAN-15-2834.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Swindall AF, Londono-Joshi AI, Schultz MJ, Fineberg N, Buchsbaum DJ, Bellis SL. ST6Gal-I protein expression is upregulated in human epithelial tumors and correlates with stem cell markers in normal tissues and colon cancer cell lines. Cancer Res. 2013;73(7):2368–78.  https://doi.org/10.1158/0008-5472.CAN-12-3424.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Zhang X, Pan C, Zhou L, Cai Z, Zhao S, Yu D. Knockdown of ST6Gal-I increases cisplatin sensitivity in cervical cancer cells. BMC Cancer. 2016;16(1):949.  https://doi.org/10.1186/s12885-016-2981-y.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Wei A, Fan B, Zhao Y, Zhang H, Wang L, Yu X, et al. ST6Gal-I overexpression facilitates prostate cancer progression via the PI3 K/Akt/GSK-3beta/beta-catenin signaling pathway. Oncotarget. 2016;7(40):65374–88.  https://doi.org/10.18632/oncotarget.11699.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Chen X, Wang L, Zhao Y, Yuan S, Wu Q, Zhu X, et al. ST6Gal-I modulates docetaxel sensitivity in human hepatocarcinoma cells via the p38 MAPK/caspase pathway. Oncotarget. 2016;7(32):51955–64.  https://doi.org/10.18632/oncotarget.10192.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Schultz MJ, Swindall AF, Wright JW, Sztul ES, Landen CN, Bellis SL. ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells. J Ovarian Res. 2013;6(1):25.  https://doi.org/10.1186/1757-2215-6-25.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Lee M, Park JJ, Ko YG, Lee YS. Cleavage of ST6Gal I by radiation-induced BACE1 inhibits golgi-anchored ST6Gal I-mediated sialylation of integrin beta1 and migration in colon cancer cells. Radiat Oncol. 2012;7:47.  https://doi.org/10.1186/1748-717X-7-47.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Swindall AF, Bellis SL. Sialylation of the Fas death receptor by ST6Gal-I provides protection against Fas-mediated apoptosis in colon carcinoma cells. J Biol Chem. 2011;286(26):22982–90.  https://doi.org/10.1074/jbc.M110.211375.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Christie DR, Shaikh FM, Lucas JAT, Lucas JA 3rd, Bellis SL. ST6Gal-I expression in ovarian cancer cells promotes an invasive phenotype by altering integrin glycosylation and function. J Ovarian Res. 2008;1(1):3.  https://doi.org/10.1186/1757-2215-1-3.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Humeniuk R, Mishra PJ, Bertino JR, Banerjee D. Epigenetic reversal of acquired resistance to 5-fluorouracil treatment. Mol Cancer Ther. 2009;8(5):1045–54.  https://doi.org/10.1158/1535-7163.MCT-08-0717.CrossRefPubMedGoogle Scholar
  27. 27.
    Srimuangwong K, Tocharus C, Yoysungnoen Chintana P, Suksamrarn A, Tocharus J. Hexahydrocurcumin enhances inhibitory effect of 5-fluorouracil on HT-29 human colon cancer cells. World J Gastroenterol. 2012;18(19):2383–9.  https://doi.org/10.3748/wjg.v18.i19.2383.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Ayinde O, Wang Z, Griffin M. Tissue transglutaminase induces epithelial-mesenchymal-transition and the acquisition of stem cell like characteristics in colorectal cancer cells. Oncotarget. 2017;8(12):20025–41.  https://doi.org/10.18632/oncotarget.15370.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Saikawa Y, Fukuda K, Takahashi T, Nakamura R, Takeuchi H, Kitagawa Y. Gastric carcinogenesis and the cancer stem cell hypothesis. Gastric cancer. 2010;13(1):11–24.  https://doi.org/10.1007/s10120-009-0537-4.CrossRefPubMedGoogle Scholar
  30. 30.
    Samadani AA, Akhavan-Niaki H. Interaction of sonic hedgehog (SHH) pathway with cancer stem cell genes in gastric cancer. Med Oncol. 2015;32(3):48.  https://doi.org/10.1007/s12032-015-0492-3.CrossRefPubMedGoogle Scholar
  31. 31.
    Lu L, Wu M, Sun L, Li W, Fu W, Zhang X, et al. Clinicopathological and prognostic significance of cancer stem cell markers CD44 and CD133 in patients with gastric cancer: a comprehensive meta-analysis with 4729 patients involved. Medicine (Baltimore). 2016;95(42):e5163.  https://doi.org/10.1097/MD.0000000000005163.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Green DR, Levine B. To be or not to be? how selective autophagy and cell death govern cell fate. Cell. 2014;157(1):65–75.  https://doi.org/10.1016/j.cell.2014.02.049.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Jiang F. Autophagy in vascular endothelial cells. Clin Exp Pharmacol Physiol. 2016;43(11):1021–8.  https://doi.org/10.1111/1440-1681.12649.CrossRefPubMedGoogle Scholar
  34. 34.
    Feng Y, Yao Z, Klionsky DJ. How to control self-digestion: transcriptional, post-transcriptional, and post-translational regulation of autophagy. Trends Cell Biol. 2015;25(6):354–63.  https://doi.org/10.1016/j.tcb.2015.02.002.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 2011;18(4):571–80.  https://doi.org/10.1038/cdd.2010.191.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Djavaheri-Mergny M, Maiuri MC, Kroemer G. Cross talk between apoptosis and autophagy by caspase-mediated cleavage of Beclin 1. Oncogene. 2010;29(12):1717–9.  https://doi.org/10.1038/onc.2009.519.CrossRefPubMedGoogle Scholar
  37. 37.
    Oldham RA, Berinstein EM, Medin JA. Lentiviral vectors in cancer immunotherapy. Immunotherapy. 2015;7(3):271–84.  https://doi.org/10.2217/imt.14.108.CrossRefPubMedGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2018

Authors and Affiliations

  1. 1.Department of General Surgery and Center of Minimal Invasive Gastrointestinal Surgery, Southwest HospitalThird Military Medical UniversityChongqingChina

Personalised recommendations